C2 Therapeutics Announces Excellent Interim Safety and Efficacy Results of Cryoballoon Ablation

//C2 Therapeutics Announces Excellent Interim Safety and Efficacy Results of Cryoballoon Ablation

C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus or BE), today announced excellent interim results for its Coldplay Cryoballoon Focal Ablation System at the Digestive Disease Week (DDW) in Chicago. Data from the study titled, “Clinical evaluation of a new CryoBalloon Focal Ablation System for the elimination of Barrett’s esophagus” were presented in a poster session today by Bas Weusten, MD, Professor of Innovative Gastrointestinal Endoscopy Senior Gastroenterologist, St. Antonius Hospital Nieuwegein, The Netherlands, and trial’s Principal Investigator.

Click here for full release.

2017-08-28T19:48:57+00:00